Skip to content

Newsroom

type
year
reltype
Illustration image.png

CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

12/19/2024 Stock exchange release
Illustration image.png

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

12/19/2024 Stock exchange release
Illustration image.png

Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

12/12/2024 Stock exchange release
Illustration image.png

142,701 Orion Corporation A shares converted into B shares

11/27/2024 Stock exchange release
Illustration image.png

Orion Group Interim Report January–September 2024

10/29/2024 Stock exchange release
Illustration image.png

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

10/24/2024 Stock exchange release
Illustration image.png

213,285 Orion Corporation A shares converted into B shares

9/20/2024 Stock exchange release
Illustration image.png

Inside information: Orion upgrades full-year outlook for 2024

9/11/2024 Stock exchange release
Illustration image.png

44,767 Orion Corporation A shares converted into B shares

8/14/2024 Stock exchange release
Illustration image.png

Orion Group Half-Year Financial Report January–June 2024

8/8/2024 Stock exchange release
Illustration image.png

Orion Corporation’s financial reporting and Annual General Meeting in 2025

8/8/2024 Stock exchange release
Illustration image.png

Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

7/17/2024 Stock exchange release
Illustration image.png

Inside information: Orion upgrades full-year outlook for 2024

7/1/2024 Stock exchange release
Illustration image.png

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

7/1/2024 Stock exchange release
Illustration image.png

Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

5/7/2024 Stock exchange release
Illustration image.png

Composition of the Nomination Committee of Orion Corporation

4/26/2024 Stock exchange release
Illustration image.png

Orion Group Interim Report January–March 2024

4/25/2024 Stock exchange release
Illustration image.png

Change in Orion Group Executive Management Board: change in Orion's group-level functions

3/22/2024 Stock exchange release